SpyGlass Pharma, Inc.
SGP
Analytical Summary
SpyGlass Pharma, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.
5-Year Financial Trajectory
QuarterlyBullish Indicators
- Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
Bearish Risks
- No bearish risks detected.
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|
| EPS Growth YoY (%) |
82.6%
Excellent
Excellent
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — | — | — |
| Net Income Growth YoY (%) |
-56.6%
Weak
Weak
Year-over-year change in net income |
— | — | — | — |
| FCF Growth YoY (%) |
81.0%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — | — | — |
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|
| Effective Tax Rate (%) (%) |
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— |
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— | — |
| FCF / Net Income (x) |
1.03x
Fair
Fair
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
0.95x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— | — |
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|
| Return on Invested Capital (%) |
-6.2%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
10.8%
Good
Good
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— | — |
| Return on Capital (%) (%) |
-6.0%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— | — | — | — |
| Return on Common Equity (%) (%) |
-5.5%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-137%)
|
— |
12.8%
Fair
Fair
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-15%)
|
— | — |
| Metric | Q1 FY2026 Mar 31, 2026 10-Q ↗ | Q4 FY2025 Dec 31, 2025 10-Q ↗ | Q1 FY2025 Mar 31, 2025 10-Q ↗ | Q4 FY2024 Dec 31, 2024 10-K ↗ | Q4 FY2023 Dec 31, 2023 10-K ↗ |
|---|---|---|---|---|---|
| Depreciation Expense (USD) | $318.00K | — | $124.00K | — | — |
| Net Income, GAAP (USD) | $-13.82M | — | $-8.82M | — | — |
| Operating Cash Flow (USD) | $-13.54M | — | $-8.20M | — | — |
Secondary lens
Benchmark Lens
Compare SGP against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare SGP against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for SGP
Return on Common Equity (%) is in the top quartile
No bearish signals detected
Percentile Rankings
How SGP compares to all companies
Peer Comparison
SGP vs similar peers
Compare SGP with peers
Stack SGP against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 3 years · 5 quarters